RENODAPT 750MG TABLET

Renodapt 750 mg Tablet is an immune suppressant with an active ingredient known as Mycophenolate mofetil. It falls under the inosine monophosphate dehydrogenase (IMPDH) inhibitor class. The medicine is used to stop organ rejection in patients who have received the organs of a donor (such as heart, kidney, and liver transplantation). It is a part of a combination treatment that includes other immunosuppressive medicines.
This medication is not recommended during pregnancy because of the risk of miscarriage or congenital disabilities. It should not be used during pregnancy unless there are other alternatives and the advantages outweigh the risks. Women of childbearing age are strongly advised to use effective contraception when taking this tablet to avoid the possibility of pregnancy. Live vaccines shouldn’t be administered while a patient takes the Renodapt 750 mg tablet because of the decreased vaccine effectiveness and the risk of infection. People taking this drug must not give blood during treatment and, at minimum, six weeks after stopping treatment. This ensures that the drug has been completely removed from the body before donating blood.
It is recommended not to use this medication if you have an allergy to it or other components. Inform your physician about heart or liver disease before beginning treatment. Since this medication weakens the body’s immune system, it increases the risk of developing skin cancer. Patients must know how to minimize UV (UV) ultraviolet (UV) light exposure. Contact your doctor right away if you notice any bruising on your skin or fever. Or any other unidentified fatigue, dizziness, eyes, or skin. Eyes vision impairment, decreased urinary output, or seizures after taking this medication. Renodapt 750 mg Tablet is an immunosuppressive drug. It could impact the infant’s immune system development and should not be used while breastfeeding. In certain situations, alternatives to medications that have an enhanced safety profile for breastfeeding can be thought of as.